This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Neutral on Honeywell Aerospace; Outperform on M&T Bank and SailPoint; Buy on Ambiq Micro; Overweight on Abbott.
Stocks · News reference
Barclays Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $120
Barclays analyst Matt Miksic initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announces Price Target of $120.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Micron To Rally Around 187%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts revised targets: upgrades for NetApp and Humana; downgrades for PJT Partners; mixed target changes for Redwood, Marvell, Yum and S&P
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight
The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.